Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Entrada Therapeutics (TRDA) EBITDA (2022 - 2025)

Entrada Therapeutics (TRDA) has 4 years of EBITDA data on record, last reported at -$39.1 million in Q4 2025.

  • For Q4 2025, EBITDA fell 33835.34% year-over-year to -$39.1 million; the TTM value through Dec 2025 reached -$143.1 million, down 318.78%, while the annual FY2025 figure was -$143.1 million, 318.78% down from the prior year.
  • EBITDA reached -$39.1 million in Q4 2025 per TRDA's latest filing, up from -$43.9 million in the prior quarter.
  • Across five years, EBITDA topped out at $54.9 million in Q2 2024 and bottomed at -$43.9 million in Q3 2025.
  • Average EBITDA over 4 years is -$11.2 million, with a median of -$20.0 million recorded in 2022.
  • Peak YoY movement for EBITDA: soared 538.39% in 2024, then tumbled 33835.34% in 2025.
  • A 4-year view of EBITDA shows it stood at -$23.9 million in 2022, then skyrocketed by 63.02% to -$8.9 million in 2023, then surged by 101.31% to $116000.0 in 2024, then crashed by 33835.34% to -$39.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA were -$39.1 million in Q4 2025, -$43.9 million in Q3 2025, and -$43.1 million in Q2 2025.